Today: Insider Selling: Momenta Pharmaceuticals Inc. (MNTA) VP Sold $14,913.97 in Stock

Today: Insider Selling: Momenta Pharmaceuticals Inc. (MNTA) VP Sold $14,913.97 in Stock

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) VP James M. Roach sold 1,091 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $13.67, for a total transaction of $14,913.97. Following the completion of the sale, the vice president now directly owns 156,056 shares of the company’s stock, valued at $2,133,285.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) opened at 14.15 on Monday. The stock has a 50 day moving average price of $12.36 and a 200-day moving average price of $11.67. The firm’s market cap is $975.74 million. Momenta Pharmaceuticals Inc. has a one year low of $7.86 and a one year high of $18.26.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.03. Momenta Pharmaceuticals had a negative return on equity of 26.55% and a negative net margin of 93.75%. The company earned $299.14 million during the quarter, compared to analyst estimates of $25.68 million. During the same period last year, the company posted ($0.44) earnings per share. The firm’s quarterly revenue was up 2067.7% compared to the same quarter last year. Analysts predict that Momenta Pharmaceuticals Inc. will post ($1.16) EPS for the current fiscal year.

MNTA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reissued a “buy” rating and issued a $18.00 price target on shares of Momenta Pharmaceuticals in a report on Thursday, November 3rd. Barclays PLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of Momenta Pharmaceuticals in a research note on Thursday, November 3rd. Aegis started coverage on shares of Momenta Pharmaceuticals in a research note on Tuesday, November 22nd. They set a “hold” rating and a $15.00 price objective for the company. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Friday, November 11th. Finally, Brean Capital set a $19.00 price objective on shares of Momenta Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $16.10.

Hedge funds have recently made changes to their positions in the company. Pacad Investment Ltd. purchased a new stake in shares of Momenta Pharmaceuticals during the second quarter worth approximately $103,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Momenta Pharmaceuticals during the second quarter worth approximately $109,000. Jane Street Group LLC purchased a new stake in shares of Momenta Pharmaceuticals during the second quarter worth approximately $109,000. Profund Advisors LLC purchased a new stake in shares of Momenta Pharmaceuticals during the third quarter worth approximately $121,000. Finally, Mason Street Advisors LLC purchased a new stake in shares of Momenta Pharmaceuticals during the second quarter worth approximately $134,000. Hedge funds and other institutional investors own 84.86% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Related posts

Leave a Comment